PNC Financial Services Group Inc. Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

PNC Financial Services Group Inc. lowered its position in Sanofi (NASDAQ:SNY) by 3.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 100,087 shares of the company’s stock after selling 3,614 shares during the period. PNC Financial Services Group Inc.’s holdings in Sanofi were worth $4,827,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. Raymond James Financial Inc. purchased a new position in Sanofi in the 4th quarter valued at $135,933,000. Jennison Associates LLC lifted its holdings in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 1.8 %

Shares of NASDAQ:SNY opened at $57.69 on Thursday. The business has a 50-day moving average price of $53.27 and a 200 day moving average price of $52.81. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $146.41 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.